哌拉西林-他唑巴坦与阿米卡星联用对支气管扩张伴感染患者的影响

Effect of Piperacillin-Tazobactam combined with Amikacin on patients with bronchiectasis and infection

目的探讨哌拉西林-他唑巴坦与阿米卡星联用对支气管扩张伴感染患者的影响。方法选取2016年2月~2018年8月我院收治的198例支气管扩张伴感染患者,按照治疗方法的不同分为对照组和观察组。对照组(98例)采用硫酸依替米星治疗,观察组(100例)采用哌拉西林-他唑巴坦与阿米卡星联用治疗。观察两组的咳嗽咳痰消失时间、体温恢复正常时间、咯血消失时间;观察两组的治疗前后第1秒用力呼气量(FEV1)、用力呼气量(FVC)和FEV1/FVC情况,观察两组的临床治疗效果。结果观察组的咳嗽咳痰消失时间、体温恢复正常时间、咯血消失时间均短于对照组,差异有统计学意义(P<0.05).两组治疗前FEV1、FVC、FEV1/FVC比较,差异无统计学意义(P>0.05),治疗后两组的FEV1、FVC、FEV1/FVC均高于治疗前,观察组治疗后FEV1、FVC、FEV1/FVC高于对照组,差异有统计学意义(P<0.05)。观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。结论哌拉西林-他唑巴坦与阿米卡星联用治疗支气管扩张伴感染患者,临床症状改善时间缩短,提高了肺功能和临床治疗效果,值得临床推广应用。

Objective To investigate the effect of Piperacillin-Tazobactam combined with Amikacin on patients with bronchiectasis and infection. Methods The clinical data of 198 patients with bronchiectasis-associated infection who treated in our hospital from February 2016 to August 2018 were selected. According to different therapeutic methods, they were divided into the control group (treated with Etimicin Sulfate, n=98) and the observation group (Piperacillin-Tazobactam combined with Amikacin, n=100). The disappearance time of cough and expectoration, the time of body temperature returning to normal, disappearance time of hemoptysis were observed between the two groups. In addition, the forced expiratory volume 1 second before and after treatment (FEV1), forced vital capacity (FVC) and FEV1/FVC were also observed as well as the clinical efficacy. Results The time of cough and expectoration disappeared, the time of body temperature returned to normal, and the time of hemoptysis disappeared in the observation group were shorter compared with those in the control group with statistical significance (P<0.05). There was no significant difference in FEV1, FVC and FEV1/FVC between the two groups before treatment. After treatment, the FEV1, FVC and FEV1/FVC in the control and observation groups were all higher than those before treatment, respectively. The FEV1, FVC and FEV1/FVC in the observation group after treatment were all higher compared with those in the control group (P<0.05). The total clinical effectiveness rate in the observation group was higher than that of the control group, the difference was statistically significant (P<0.05). Conclusion Piperacillin-Tazobactam combined with Amikacin in the treatment of patients with bronchiectasis and infection can shorten the improvement time of clinical symptoms, enhance the lung function and clinical efficacy, and is worthy of clinical application.